

# evidence based guidelines

## MEDICATIONS for OPIOID USE DISORDER

### GENERAL

**Medication for Opioid Use Disorder (MOUD):** reduces illicit opioid use, retains people in treatment, and reduces the risk of opioid overdose death better than treatment with placebo or no medication.

**MOUD should be part of a comprehensive rehabilitation program** – see “Substance Use Disorder” guideline

**Preventive naloxone (Narcan)** available by prescription, through hospital pharmacy, or FREE community distribution centers:

Fridays 1PM -4 PM at Skip's Pharmacy; 700 Michigan Ave Holland

Fridays 10AM-12PM at Grand Haven Community Mental Health; 1111 Fulton St #1

FREE mail order at [naloxoneforall.org/michigan](http://naloxoneforall.org/michigan)

### NALTREXONE

Full opioid antagonist – Patient must be off all opioids for 7-14 days prior to initiating

Dosing: 50mg oral once daily or 380mg IM (e.g. Vivitrol) every 4 weeks

### BUPRENORPHINE

Partial opioid agonist with a higher receptor affinity than other opioids

May precipitate withdrawal symptoms in those actively using other opioids

At low doses each 1mg gives similar analgesia as 20-30mg of morphine

Has a “ceiling” effect for higher doses with no further benefit/harm above 24mg/day

Can give euphoria and over-sedation especially with IV form or in opioid naïve patients

**Can cause fatal overdose in children or if co-administered with alcohol/benzodiazepines**

**Formulations:**

Combination with naloxone sublingual strips (e.g Suboxone)

Combination with naloxone sublingual tablets (e.g Suboxone, Zubsolv)

– Naloxone is NOT absorbed sublingually, but WILL inactivate opioid effect intravenously

– Combination is preferred if clinically appropriate to prevent diversion to IV use

Stand-alone buprenorphine sublingual tablets (e.g Subutex)

Injectable -SC/IM/IV (e.g. Sublocade, Brixadi)

**Induction:**

Starting moderate or high dose buprenorphine for the first time while a patient is actively using other opioids may cause precipitated withdrawal. To prevent this uncomfortable reaction, various induction methods are used. See: [A practical guide for buprenorphine initiation in the primary care setting \(Cleveland Clinic Journal of Medicine Sep 2023, 90 \(9\) 557-564\)](#)

Be cautious to avoid over-sedation especially if patient has also been abusing sedatives or Etoh

The majority of patients will receive relief with 8mg or 16mg of buprenorphine/day

Treat withdrawal symptoms if necessary.

Nausea: ondansetron, promethazine, prochlorperazine  
Insomnia: trazodone, melatonin, gabapentin, quetiapine

Shakes/sweats, hypertension: clonidine 0.1 q4hrs prn  
Anxiety: hydroxyzine, buspirone, gabapentin, SSRIs

**Maintenance:**

Begin with frequent visits, routine point of care drug testing, and small supplies of medications.

Relax oversight as patient demonstrates successful recovery.

Instead of dismissal for evidence of relapse or diversion, increase oversight (shorter f/u, random testing/med count, supervised administration, monthly SC treatment) or refer to a higher level of care

### METHADONE

Must be prescribed at a federal regulated treatment center

– Western Michigan Comprehensive Treat. Ctr.: 833-919-2179 [western-michigan-comprehensive-treatment-center/](http://western-michigan-comprehensive-treatment-center/)

– Muskegon Recovery Center: 231-767-1921 [chemyhealth.org/locations/muskegon-recovery-center/](http://chemyhealth.org/locations/muskegon-recovery-center/)

### RESOURCES

OPEN (Overdose Prevention Engagement Network): [michigan-open.org/programs/request-a-consultation/](http://michigan-open.org/programs/request-a-consultation/)

SAMHSA (Substance Abuse and Mental Health Serv. Admin): [samhsa.gov/medications-opioid-use-disorder](http://samhsa.gov/medications-opioid-use-disorder)